- 著者
-
Akira Sato
Michio Sata
Kenji Ikeda
Takashi Kumada
Namiki Izumi
Yasuhiro Asahina
Yukio Osaki
Kazuaki Chayama
Shuichi Kaneko
Akito Sakai
Morikazu Onji
Yoichi Hiasa
Takumi Omura
Itaru Ozeki
Osamu Yokosuka
Shuichiro Shiina
Mariko Itsubo
Shuhei Nishiguchi
Katsuharu Hirano
Tatsuya Ide
Shotaro Sakisaka
Takahiro Yamasaki
Isao Hidaka
Masatoshi Tanaka
Soo Ryang Kim
Takafumi Ichida
- 出版者
- 一般社団法人 日本内科学会
- 雑誌
- Internal Medicine (ISSN:09182918)
- 巻号頁・発行日
- vol.52, no.24, pp.2701-2706, 2013 (Released:2013-12-15)
- 参考文献数
- 32
- 被引用文献数
-
4
14
Objective We attempted to elucidate the clinical features of chronic hepatitis C patients who develop hepatocellular carcinoma (HCC) after achieving a sustained viral response (SVR) to interferon (IFN) therapy. Methods The clinical features of 130 patients at 19 hospitals who developed HCC after obtaining an SVR were retrospectively reviewed. Results Overall, 107 (82%) of the 130 patients were men, with 92 (71%) being ≥60 years of age and 76, 38 and 16 developing HCC within 5, 5-10 and 10-16.9 years after IFN therapy, respectively. Before receiving IFN therapy, 92 (71%) patients had cirrhosis and/or a low platelet count (<15×104 cells/μL). Lower albumin (<3.9 g/dL) and higher alpha fetoprotein (AFP) (≥10 ng/mL) levels were identified in a multivariate analysis to be independent variables of the development of HCC within five years after IFN therapy. Among 4,542 SVR patients, HCC occurred in 109 (2.4%) during a 5.5-year follow-up period, thus resulting in an occurrence rate of 4.6% for men and 0.6% for women. Conclusion SVR patients with lower albumin or higher AFP levels require careful assessments to prevent early HCC development after IFN therapy. HCC occurrence within >10 years of IFN therapy is not uncommon, and the risk factors remain uncertain, thus suggesting that all SVR patients should undergo long-term follow-up examinations for HCC development.